Review
Psychiatry
Rachel E. Davis-Martin, Sheila M. Alessi, Edwin D. Boudreaux
Summary: Biosensors play a crucial role in monitoring physiological indicators of intoxication and aiding in treatment recommendations for alcohol use disorders. Wearable technology-based research is increasingly focusing on identifying and tracking alcohol consumption, with potential for further exploration in understanding and treating alcohol use disorders.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Substance Abuse
Jorge S. Martins, Nia Fogelman, Stephanie Wemm, Seungju Hwang, Rajita Sinha
Summary: This study found that alcohol craving and withdrawal symptoms may predict higher risk of heavy drinking during outpatient treatment. The results highlight the importance of assessing alcohol craving and withdrawal symptoms at the beginning of outpatient treatment and developing targeted treatments to address their impact on drinking outcomes.
DRUG AND ALCOHOL DEPENDENCE
(2022)
Review
Health Care Sciences & Services
Jessica L. Taylor, Samantha Johnson, Ricardo Cruz, Jessica R. Gray, Davida Schiff, Sarah M. Bagley
Summary: This article discusses strategies for integrating evidence-based harm reduction principles and interventions into outpatient, primary care-based OUD treatment settings. Specific tools are provided for supporting safer injection practices, assessing risks and benefits of continuing medications, promoting a non-stigmatizing program culture, and addressing the needs of specific populations.
JOURNAL OF GENERAL INTERNAL MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Ming-Fen Ho, Cheng Zhang, Irene Moon, Brandon J. J. Coombes, Joanna Biernacka, Michelle Skime, Doo-Sup Choi, Paul E. E. Croarkin, Mark A. A. Frye, Quyen Ngo, Cedric Skillon, Tyler S. S. Oesterle, Victor M. M. Karpyak, Hu Li, Richard M. M. Weinshilboum
Summary: This study aimed to identify biomarkers associated with acamprosate treatment response in patients with alcohol use disorder (AUD) using proteomics and RNA sequencing. The findings suggest that baseline plasma TNFSF10 concentration is associated with alcohol craving intensity and acamprosate treatment outcomes. In addition, inflammation-related pathways are highly associated with relapse during acamprosate treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Clinical Neurology
Victor M. Tang, Dengdeng Yu, Cory R. Weissman, Brett D. M. Jones, Guan Wang, Matthew E. Sloan, Daniel M. Blumberger, Zafiris J. Daskalakis, Bernard Le Foll, Daphne Voineskos
Summary: This study examined the treatment outcomes of patients with major depressive disorder (MDD) and comorbid alcohol use disorder (AUD). The results showed that patients with comorbid AUD had poorer response to antidepressant treatment. Addressing this comorbidity requires unique assessment and treatment approaches.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Medicine, General & Internal
Kevin Y. Xu, Ned Presnall, Carrie M. Mintz, Jacob T. Borodovsky, Nisha R. Bhat, Laura J. Bierut, Richard A. Grucza
Summary: This study suggests that opioid use disorder (OUD) medication is associated with fewer admissions for alcohol-related acute events in patients with OUD with co-occurring alcohol use disorder (AUD).
Article
Substance Abuse
Julie M. Croff, Micah L. Hartwell, Ashleigh L. Chiaf, Erica K. Crockett, Isaac J. Washburn
Summary: This study demonstrates that transdermal alcohol sensors are moderately reliable when paired with self-report, suggesting that this objective data collection method may enhance the ability to understand alcohol consumption patterns among adolescents.
DRUG AND ALCOHOL REVIEW
(2021)
Review
Substance Abuse
Caroline Gregory, Yelena Chorny, Shelley L. McLeod, Rohit Mohindra
Summary: This review explores the barriers that prevent patients from obtaining medication for addiction treatment (MAT) for alcohol use disorder (AUD) in outpatient or residential settings. The study found that patients have inadequate knowledge and concerns about the efficacy and complexity of prescribing. Treatment philosophy and stigma, as well as medication accessibility such as formulary restrictions and geographical and socioeconomic barriers, also contribute to the barriers faced by patients. Efforts should be made to increase the use of evidence-based pharmacotherapeutics for AUD and further research is needed to understand and overcome these barriers.
JOURNAL OF ADDICTION MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Leigh C. Walker, Kade L. Huckstep, Howard C. Becker, Christopher J. Langmead, Andrew J. Lawrence
Summary: Emerging evidence suggests muscarinic acetylcholine receptors are potential targets for treating alcohol use disorder. This review integrates findings from medicinal chemistry, molecular biology, addiction, and learning/cognition fields to explore the potential of muscarinic receptor ligands in treating cognitive dysfunction, motivation to consume alcohol, and relapse associated with alcohol use disorder. The dysfunctional role of cholinergic system in alcohol use disorder is discussed, along with the potential therapeutic targets of specific muscarinic receptors, particularly M-4 and M-5 receptors. The use of subtype-selective allosteric modulators is proposed as a strategy to target these receptors, and the potential repurposing of muscarinic receptor modulators for alcohol use disorder is highlighted.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Article
Health Care Sciences & Services
Pedro Gamito, Jorge Oliveira, Marcelo Matias, Elsa Cunha, Rodrigo Brito, Paulo Ferreira Lopes, Alberto Deus
Summary: This study aimed to investigate the feasibility of using VR-based cognitive training to improve the cognitive function of patients with AUD, as well as estimating the effect size for future RCTs. Results suggested that cognitive training using VR contributed to enhancing attention and cognitive flexibility in patients recovering from AUD.
JOURNAL OF MEDICAL INTERNET RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
Francisco D. Rodriguez, Manuel Lisardo Sanchez, Rafael Covenas
Summary: Harmful alcohol use, known as alcohol use disorders (AUDs) in the DSM-5 classification, has various negative effects on individuals and their social and familial environments. Alcohol addiction is characterized by compulsive drinking and negative emotional states during withdrawal, often leading to relapses. The complexity of AUD involves multiple factors, including the use of other psychoactive substances. Ethanol and its metabolites directly impact tissues and may disrupt brain neurotransmission, immunity, and cell repair pathways. The review focuses on the role of neurotensin (NT) in alcohol addiction and the potential use of nonpeptide ligands to modulate the NT system in animal models of harmful drinking behavior.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Substance Abuse
Rocio Villa, Ashkan Espandian, Pilar A. Saiz, Monica Astals, Joana K. Valencia, Emilia Martinez-Santamaria, Sandra Alvarez, Maria Paz Garcia-Portilla, Julio Bobes, Gerardo Florez
Summary: This study aimed to analyze the presence of cognitive impairment associated with alcohol consumption in patients seeking outpatient treatment for moderate or severe alcohol use disorder. The results showed that patients with moderate or severe alcohol use disorder performed significantly worse in cognitive functions compared to healthy controls. Those with more impulsivity, longer duration of alcohol abuse, and higher addiction levels experienced greater cognitive deterioration.
Article
Nutrition & Dietetics
Julia de Ternay, Agathe Larrieu, Laura Sauvestre, Solene Montegue, Monique Guenin, Christophe Icard, Benjamin Rolland
Summary: Improving physical activity in patients with alcohol use disorder is essential for improving drinking outcomes and quality of life. Patients with insufficient baseline physical activity show markers of severity and should receive physical exercise interventions as part of a multimodal treatment program.
Review
Biochemistry & Molecular Biology
Francisco Navarrete, Maria S. Garcia-Gutierrez, Ani Gasparyan, Daniela Navarro, Jorge Manzanares
Summary: The discovery of CB2r in brain areas related to reward system and its influence on anxiety and depression behavioral traits in animal studies make CB2r modulation a promising area for drug research in treating addictive disorders.
Article
Psychiatry
Kaisa E. Luoto, Antero Lassila, Esa Leinonen, Olli Kampman
Summary: The severity of symptoms and comorbid disorders were found to predict better treatment response, suggesting that the intervention was more effective in patients with severe symptoms. Patients with depression should be treated effectively regardless of having concomitant AUD. The results of this study suggest that BA combined with MI should be one of the treatment options for this dual pathology.
Article
Substance Abuse
Sheila M. Alessi, Carla J. Rash, Nancy M. Petry
NICOTINE & TOBACCO RESEARCH
(2017)
Article
Substance Abuse
Carla J. Rash, Nancy M. Petry, Sheila M. Alessi, Nancy P. Barnett
Article
Endocrinology & Metabolism
Sheila M. Alessi, Nicole C. Foster, Carla J. Rash, Michelle A. Van Name, William V. Tamborlane, Eda Cengiz, Sarit Polsky, Julie Wagner
CANADIAN JOURNAL OF DIABETES
(2020)
Article
Substance Abuse
Keith Humphreys, Nicolas B. Barreto, Sheila M. Alessi, Kathleen M. Carroll, Paul Crits-Christoph, Dennis M. Donovan, John F. Kelly, Richard S. Schottenfeld, Christine Timko, Todd H. Wagner
DRUG AND ALCOHOL DEPENDENCE
(2020)
Review
Psychiatry
Rachel E. Davis-Martin, Sheila M. Alessi, Edwin D. Boudreaux
Summary: Biosensors play a crucial role in monitoring physiological indicators of intoxication and aiding in treatment recommendations for alcohol use disorders. Wearable technology-based research is increasingly focusing on identifying and tracking alcohol consumption, with potential for further exploration in understanding and treating alcohol use disorders.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Medicine, Research & Experimental
Fiene Marie Kuijper, Uma Mahajan, Seul Ku, Daniel A. N. Barbosa, Sheila M. Alessi, Sherman C. Stein, Kyle M. Kampman, Brandon S. Bentzley, Casey H. Halpern
Summary: The study found that deep brain stimulation (DBS) for treating cocaine use disorder (CUD) is not cost-effective in the short term (one year), but may become a cost-effective treatment option in longer timelines.
Article
Endocrinology & Metabolism
Carla J. Rash, Sheila M. Alessi, Nicole Foster, William Tamborlane, Michelle A. Van Name, Julie A. Wagner
Summary: This study found that tobacco use among individuals with diabetes is associated with worse clinical indicators, while former tobacco users did not show these negative associations. These findings can inform tobacco cessation interventions by highlighting diabetes-specific motivators.
JOURNAL OF DIABETES AND ITS COMPLICATIONS
(2022)
Article
Psychology, Clinical
Lourah M. Kelly, Carla J. Rash, Sheila M. Alessi, Kristyn Zajac
JOURNAL OF SUBSTANCE ABUSE TREATMENT
(2020)
Article
Substance Abuse
Carla J. Rash, Sheila M. Alessi, Kristyn Zajac
PSYCHOLOGY OF ADDICTIVE BEHAVIORS
(2020)
Article
Substance Abuse
Sheila M. Alessi, Carla J. Rash, Linda S. Pescatello
PSYCHOLOGY OF ADDICTIVE BEHAVIORS
(2020)
Article
Psychology, Clinical
Nancy M. Petry, Sheila M. Alessi, Carla J. Rash, Danielle Barry, Kathleen M. Carroll
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY
(2018)
Article
Substance Abuse
Carla J. Rash, Nancy M. Petry, Sheila M. Alessi
PSYCHOLOGY OF ADDICTIVE BEHAVIORS
(2018)
Article
Psychology, Clinical
Sheila M. Alessi, Carla J. Rash
JOURNAL OF SUBSTANCE ABUSE TREATMENT
(2017)
Article
Substance Abuse
Nancy M. Petry, Sheila M. Alessi, Todd A. Olmstead, Carla J. Rash, Kristyn Zajac
PSYCHOLOGY OF ADDICTIVE BEHAVIORS
(2017)
Article
Substance Abuse
Atefeh Bakhtazad, Afsaneh Asgari Taei, Fatemeh Parvizi, Mehdi Kadivar, Maryam Farahmandfar
Summary: This study found that repeated morphine pretreatment can reverse the impairment of spatial learning and memory caused by ethanol, and this effect may be explained by the modulation of CaMKII and BDNF expressions in the hippocampus and amygdala.